TTR

TTR Full Name

Transthyretin

TTR Introduction

For many researchers and clinicians working in neurodegeneration, cardiomyopathy, or protein misfolding disorders, transthyretin (TTR) has evolved from being viewed as a simple transport protein into a highly complex therapeutic target with systemic biological importance. TTR is a conserved homotetrameric plasma protein primarily synthesized in the liver, choroid plexus, and retinal pigment epithelium. Its classical physiological role involves the transport of thyroxine (T4) and retinol through binding to retinol-binding protein, helping maintain endocrine balance, neuronal metabolism, and vitamin A homeostasis. However, growing evidence suggests that TTR is far more than a carrier molecule. Studies increasingly associate TTR with neuroprotection, axonal regeneration, cognitive maintenance, glucose metabolism, skeletal integrity, and tissue repair. In the central nervous system, TTR appears to participate in the clearance or modulation of toxic protein aggregates, including amyloid-β peptides, making it highly relevant to aging-associated neurological decline. These findings are particularly important because many patients with neurodegenerative diseases experience delayed diagnosis and limited therapeutic benefit, creating strong interest in targets that bridge metabolism, proteostasis, and neuronal survival.

The biological importance of TTR becomes even more apparent in transthyretin amyloidosis (ATTR), a progressive and often underdiagnosed disorder caused by destabilization and misfolding of the TTR tetramer. When the tetramer dissociates into unstable monomers, these proteins can aggregate into amyloid fibrils that accumulate in peripheral nerves, the heart, gastrointestinal tissues, and other organs. Hereditary ATTR (ATTRv), driven by pathogenic mutations in the TTR gene, frequently presents with progressive sensory-motor neuropathy, autonomic dysfunction, or restrictive cardiomyopathy, while wild-type ATTR (ATTRwt) is increasingly recognized in aging populations, especially among patients with unexplained heart failure or preserved ejection fraction. One of the major clinical challenges is that symptoms often mimic more common diseases, resulting in years of diagnostic delay and irreversible tissue damage before treatment begins. Different TTR variants may preferentially affect the nervous system, the myocardium, or both, creating highly heterogeneous disease phenotypes. Because ATTR is now considered a treatable disease, the identification of TTR mutations, amyloid deposition patterns, and early biomarkers has become essential for precision medicine strategies and improved patient outcomes.

Recent therapeutic advances have transformed TTR into one of the most actively investigated targets in rare disease and protein stabilization research. Modern treatment approaches include TTR stabilizers that prevent tetramer dissociation, RNA-targeting therapies that reduce hepatic TTR production, and emerging gene-editing technologies designed to silence mutant TTR expression. Yet this therapeutic progress also raises an important biological concern: completely suppressing TTR may unintentionally interfere with its protective physiological functions. Increasing evidence links low circulating TTR levels with higher mortality risk, cardiovascular disease progression, frailty, osteoporosis, metabolic dysfunction, and certain malignancies. Researchers are therefore paying closer attention to the balance between reducing amyloid toxicity and preserving normal TTR-mediated neuroprotective and endocrine functions. This dual role makes TTR especially compelling in translational medicine, because it represents both a disease-causing protein and a potentially protective factor in systemic health. As interest grows in amyloidosis, neurodegeneration, and healthy aging, TTR continues to emerge as a critical molecular target connecting protein stability, organ protection, and long-term disease management.

Alternate Names for TTR

TTR; Transthyretin; CTS; CTS1; PALB; TBPA; HEL111; HsT2651

• 1.Gertz MA, et al.; Unravelling the myriad physiologic roles of transthyretin: critical considerations for treating transthyretin amyloidosis. Ann Med. 2025, 57(1):2536755.
  2.Liz MA, et al.; A Narrative Review of the Role of Transthyretin in Health and Disease. Neurol Ther. 2020, 9(2):395-402.